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Abstract
α7 nicotinic acetylcholine receptors (nAChRs) and N-methyl-D-aspartate receptors
(NMDARs) are key mediators of central cholinergic and glutamatergic neurotransmission,
respectively. In addition to numerous well-established functional interactions between α7
nAChRs and NMDARs, the two receptors have been proposed to form a multimeric com-
plex, and in the present study we have investigated this putative α7 nAChR/NMDAR assem-
bly in human and murine brain tissues. By α-bungarotoxin (BGT) affinity purification, α7 and
NMDAR subunits were co-purified from human and murine cortical and hippocampal homog-
enates, substantiating the notion that the receptors are parts of a multimeric complex in the
human and rodent brain. Interestingly, the ratios between GluN1 and α7 levels in BGT pull-
downs from cortical homogenates from Alzheimer’s disease (AD) brains were significantly
lower than those in pull-downs from non-AD controls, indicating a reduced degree of α7
nAChR/NMDAR complex formation in the diseased tissue. A similar difference in GluN1/α7
ratios was observed between pull-downs from cortical homogenates from adult 3xTg-AD and
age-matched wild type (WT) mice, whereas the GluN1/α7 ratios determined in pull-downs
from young 3xTg-AD and age-matched WT mice did not differ significantly. The observation
that pretreatment with oligomeric amyloid-β1–42 reduced GluN1/α7 ratios in BGT pull-downs
from human cortical homogenate in a concentration-dependent manner provided a plausible
molecular mechanism for this observed reduction. In conclusion, while it will be important to
further challenge the existence of the putative α7 nAChR/NMDAR complex in future studies
applying other methodologies than biochemical assays and to investigate the functional impli-
cations of this complex for cholinergic and glutamatergic neurotransmission, this work sup-
ports the formation of the complex and presents new insights into its regulation in healthy and
diseased brain tissue.
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Introduction
Glutamate (Glu) and acetylcholine (ACh) are major neurotransmitters in the central nervous
system (CNS), where both are directly involved in or regulate a wide spectrum of physiological
processes. Dysfunctions in glutamatergic and cholinergic neurotransmission have been impli-
cated in numerous pathological states, and modulation of glutamatergic and/or cholinergic
mechanisms holds considerable therapeutic potential when it comes to numerous cognitive,
psychiatric and neurodegenerative disorders [1–4]. Both Glu and ACh mediate their physio-
logical effects through highly heterogeneous families of G-protein coupled receptors (GPCRs)
and ligand-gated cation channels (LGICs). Glu acts through three classes of LGICs: the N-
methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)
and kainate receptors. The receptors are heteromeric complexes assembled by four subunits,
with the prototypic NMDA receptor (NMDAR) being comprised of two GluN1 subunits and
two GluN2 subunits (GluN2A-2D) [5]. The fast cholinergic signalling in the CNS is mediated
by the neuronal nicotinic ACh receptors (nAChRs) that are homo- and heteropentameric
complexes assembled from α2-α10 and β2-β4 subunits, with the homomeric α7 nAChR being
one of the two major physiological neuronal nAChR subtypes [3, 4].
A substantial amount of experimental data has established NMDARs and α7 nAChRs as key
contributors to the glutamatergic and cholinergic components of cognitive functions. NMDARs
are the key mediators of the long-term potentiation (LTP) believed to be at the very core of syn-
aptic plasticity and cognition [6], and a close link between α7 nAChRs and glutamatergic trans-
mission exists due to functional interactions at numerous levels, with presynaptic α7 nAChRs
facilitating Glu release throughout the brain and α7 nAChRs being capable of modulating synap-
tic plasticity through NMDARs [3, 7–10]. In addition to this functional cross-talk and synergy
between the two receptors, Liu and colleagues have found NMDARs and α7 nAChRs to assem-
ble into receptor complexes [11–13]. The GluN2A subunit has been shown to coimmunoprecipi-
tate with the α7 subunit from rat hippocampal homogenate, and GluN2A and α7 have been
proposed to form a direct protein-protein interaction rooted in the carboxy terminal of GluN2A
and a segment of the second intracellular loop of α7 [11]. Based on studies applying a peptide
(α7-pep2) that selectively interferes with the α7 nAChR/NMDAR assembly, the complex forma-
tion has been proposed to underlie α7 nAChR-mediated augmentation of NMDAR-mediated
whole-cell currents and miniature excitatory postsynaptic currents of LTP in cultured hippo-
campal cultures [12]. Moreover, the α7 nAChR/NMDAR coupling has been proposed to be
important for cue-induced nicotine reinstatement and to affect some cognitive domains [11, 12].
The putative complex formation between NMDARs and α7 nAChRs and the possibilities
for direct cross-talk between the two receptors as well as between the glutamatergic and cho-
linergic systems arising from it present interesting perspectives. In the present study, we have
investigated the assembly of the complex in murine and human cortical and hippocampal
brain tissues in affinity purification experiments. The degrees of α7 nAChR/NMDAR complex
formation in cortical homogenates from healthy control (non-Alzheimer’s Disease [non-AD])
and AD humans and in wild-type (WT) and 3xTg-AD mice brain cortical homogenates have
been also compared, and the molecular mechanism underlying the observed differences in
complex formation between these tissues has been investigated.
Materials and methods
Chemicals
Bovine serum albumin (BSA) and all chemicals used in the buffers were obtained from Sigma-
Aldrich (Brøndby, Denmark). α-bungarotoxin (BGT) was obtained from Tocris Cookson
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(Bristol, UK). The Aβ1–42, α7-pep1 and α7-pep2 peptides were purchased from Dg-Peptide
Co. (Hang Zhou City, China).
Human brain tissue
Human temporal cortical and hippocampal tissues used for the experiments in Figs 1B and 5
were obtained by surgery from subjects with medically intractable temporal lobe epilepsy with
hippocampal onset. The hippocampus tissues were obtained from two subjects (1 female aged
41 years and 1 male aged 54 years), and the cortical tissues were obtained from four subjects (3
females aged 41, 55 and 57 years and 1 male aged 54 years). Written informed consent was
obtained from all patients before surgery. The study was approved by the Ethical Committee
in the Capital Region of Denmark (H-2-2011-104) and performed in accordance with the Dec-
laration of Helsinki. The tissues were dissected and immediately frozen on dry ice and stored
at -80˚C until use. The neuropathologic examinations of the neocortex from all patients were
normal.
The post mortem brain tissues used for the experiments depicted in Fig 2 were from medial
frontal gyrus of 7 Alzheimer Disease (AD) subjects and 8 control (non-AD) subjects (Table 1).
These tissues were obtained from the Netherlands Brain Bank (Amsterdam, The Netherlands)
and were the same as those used in a previous study [14]. Autopsies were performed on donors
from whom written informed consent had been obtained either from the donor or direct next
of kin. All AD subjects were confirmed by standard clinical [15] and neuropathologic [15, 16]
diagnosis criteria.
Murine brain tissue
The cortical and hippocampal tissues from NMRI mice (2 females aged 14 weeks old and 2
males aged 10 weeks old) were used for the experiments depicted in Fig 1A and 1D. α7 nAChR
knockout (KO) mice and WT littermates (C57BL/6 background) were purchased from The
Jackson Laboratories and bred at Virginia Commonwealth University (Dr. Imad Damaj), and
two α7 KO mice (1 male aged 8 weeks and 1 female aged 12 weeks) and two age- and sex-
matched WT littermates (controls) were used for the experiments depicted in Fig 1C. Frontal
cortices from adult (76–84 weeks old) 3×Tg-AD mice (n = 8) and age- and sex-matched WT
controls (n = 8) were dissected and used for experiments depicted in Fig 3, and frontal cortices
from young (22–24 weeks old) 3×Tg-AD mice (n = 8) and age- and sex-matched WT litter-
mates (controls) (n = 7) were dissected and used for experiments depicted in Fig 4 [17]. All
mice were sacrificed by decapitation, and their brains were separated and stored at -80˚C. The
manager of the vivarium had all the necessary licenses for housing laboratory animals.
Preparation of soluble oligomeric Aβ1–42
Freshly made Aβ1–42 oligomers were prepared according to previously described methods [18,
19]. Briefly, Aβ1–42 was dissolved at a concentration of 1 mM in 1,1,1,3,3,3-hexafluoro-2-pro-
panol and aliquoted. The volatile solvent was allowed to evaporate at RT (for about 2 h) until
no visible liquid was left in the tube, leaving a film of Aβ1–42 in the tubes that were stored at
-80˚C. Immediately prior to use, the film was re-suspended in anhydrous DMSO (to a concen-
tration of 5 mM) by 20 sec vortexing at RT, and diluted to the desired final concentration in
phosphate-buffered saline (PBS). The solutions were vortexed, sonicated for 2 min, incubated
for 24 h at 4˚C, and immediately used for the experiment. The sizes of the Aβ1–42 oligomers
formed were investigated by native western blotting and by transmission electron microscopy
and the preparation was found to contain Aβ1–42 10- and 16-mers (S1 Fig).
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Fig 1. Complex formation between α7 nAChR and NMDAR in murine and human cortex and hippocampus. (A-B) Affinity purification with agarose
beads covalently coupled with α-bungarotoxin (BGT) or BSA (Ctrl) on homogenates from murine (A) and human (B) cortical (CTX) and hippocampal (Hippo)
tissues. Total lysates (Input) and pulled-down (Pull Down) samples were submitted to gel electrophoresis and Western blotting followed by detection using
antibodies for GluN1, α7 nAChR and GABAAR α1 subunits. The gels in A and B are representative for different experiments using tissues from 4 different
mouse hippocampi, 4 different mouse cortices, 2 different human hippocampi and 2 different human cortices. (C) Total lysates (Input) and pulled-down (Pull
Down) samples from WT and α7 KO mouse cortical homogenates were submitted to gel electrophoresis and Western blotting followed by detection using
antibodies for GluN1, α7 nAChR and GABAAR α1 subunits and β-actin. (D) Total lysates (Input) and pulled-down (Pull Down) samples from mouse cortical
homogenates pretreated with buffer or buffer supplemented with α7-pep2 (10 μM and 50 μM) or α7-pep1 (10 μM and 50 μM) were submitted to gel
electrophoresis and Western blotting followed by detection using antibodies for GluN1, GluN2A, α7 nAChR and GABAAR α1 subunits. (E) Quantification of α7
α7 nAChR/NMDAR complex formation in healthy and Alzheimer brain tissue
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Membrane protein fractionation and pull-down assay
Membrane protein lysates were prepared from human and mice tissues based on protocols
adapted from previous studies [20, 21]. The tissues were homogenized in 1.5 ml (cortex) or 1
ml (hippocampus) of lysis buffer (50 mM Tris, 50 mM NaCl, 5 mM EDTA, 5 mM EGTA, 3 μl/
ml protease inhibitor cocktail (Sigma), pH 7.5) using a PT1200C polytron blender (Kinema-
tica, Luzern, Switzerland) for 4 × 5 sec. The lysates were centrifuged in an Optima™ LE-80K
ultracentrifuge (Beckman Coulter) at 36.000 rpm at 4˚C for 40 min, after which the superna-
tant was discarded. The pellets were then resuspended in the same volume of lysis buffer con-
taining 2% Triton X-100, homogenized again for 4 × 5 sec and incubated for 2 h at 4˚C on a
rotor (15 rpm). Then the samples were centrifuged at 36.000 rpm at 4˚C for 40 min, and the
resulting supernatants were used for affinity purification (the pull-down assay). Total protein
concentrations were determined colorimetrically using the Pierce 660 nm Protein Assay
Reagent (Thermo Scientific, Rockford, IL).
The affinity purification using the pull-down method is based on the use of BGT-coated
beads, with BSA-coated beads being used as negative control. In brief, BGT or BSA was
dissolved in coupling buffer (0.1 M NaHCO3 buffer containing 0.5 M NaCl, pH 8.5) at 2
mg/ml. Next, the bait proteins were coupled to pre-washed N-hydroxysuccinimide
(NHS)-activated agarose beads slurry in Pierce™ centrifuge columns (both Thermo Scien-
tific) in a 1:1 (v/v) ratio. The bait proteins were then incubated with the beads for 2 h at RT
while rotating. Successful coupling was confirmed by subsequent determination of BGT
and BSA in the flow through. In those cases where coupling efficacy for BGT or BSA was
found to be lower than ~85%, the coupling step was repeated until this coupling efficacy
was achieved. Subsequently, the coupled beads were suspended in coupling buffer supple-
mented with 1 M ethanolamine for 30 min at RT while rotating in order to block any
unreacted NHS-amino groups. Quenched coupled beads were then subjected to three
washing rounds consisting of alternating washes with 1 ml coupling buffer and 1 ml 0.1 M
acetate buffer (pH 4). After a final wash with coupling buffer, the beads were washed twice
with lysis buffer.
From each sample, 100 μl beads (50% suspended in lysis buffer) were incubated with
1000 μg total protein in a total volume of 1500 μl lysis buffer for 17–20 h at 4˚C on a rotor (15
rpm). In the experiments with the α7-pep2/α7-pep1 and Aβ1–42 peptides, the tissue lysates
were preincubated with buffer or buffer supplemented with various concentrations of the
respective peptides for 20 min at RT (α7-pep2 and α7-pep1) or for 1 h on ice (Aβ1–42) on a
rotor (15 rpm) prior to this 17–20 h incubation. The time periods and temperatures used for
these preincubations were based on those used in previous studies with α7-pep2/α7-pep1 and
Aβ1–42 [11, 21]. The following day, the beads in the columns were washed with 3 x 500 μl phos-
phate buffer A (1 M NaCl, 8 mM Na2HPO4, 2 mM NaH2PO4, 0.5% Triton X-100, pH 7.5),
and then with 3 x 500 μl phosphate buffer B (0.1 M NaCl, 8 mM Na2HPO4, 2 mM NaH2PO4,
0.5% Triton X-100, pH 7.5) and vortexed for 10 sec in between these washes. The beads in col-
umns were collected in PBS, transferred into tubes and immediately processed for western
blotting.
pulled-down and GluN1 and GluN2A pulled-down (normalized to the pulled-down α7) from mouse cortical homogenates pretreated with buffer or buffer
supplemented with α7-pep2 (10 μM and 50 μM) or α7-pep1 (10 μM and 50 μM). Values are given as mean ± SEM (n = 3–4, i.e. 3–4 different mouse cortices,
the experiment was performed once). *p <0.05 and **p < 0.01 indicate statistically significant difference from the vehicle-treated group in Kruskal-Wallis test
with Dunn’s multiple comparison test. #p <0.05 indicates statistically significant difference between GluN1/α7 Pulled-down ratios between α7-pep2 (50 μM) or
α7-pep1 (50 μM) in unpaired t-tests.
https://doi.org/10.1371/journal.pone.0189513.g001
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Western blotting
Diluted protein samples and pulled-down agarose beads were boiled with loading buffer (in
final concentrations of 60 mM Tris, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (v/v) mercaptoetha-
nol, 0.025% (w/v) bromophenol blue, pH 6.8) at 96˚C for 10 min, and then allowed to cool on
ice for 5 min. Equal amounts of protein (6 μg/lane) were loaded onto gel electrophoresis using
Any kDTM precast polyacrylamide gels (Biorad, Hercules, CA). Proteins on the gel were subse-
quently transferred to midi-size polyvinylidene fluoride (PVDF) membrane (Bio-Rad, Hercules,
CA) with transfer buffer using Trans-Blot1 TurboTM Transfer system (Bio-Rad, Hercules,
Fig 2. Complex formation between α7 nAChR and NMDAR in the AD brain. Affinity purification performed with agarose beads covalently
coupled with α-bungarotoxin (BGT) or BSA (Ctrl) using homogenized postmortem surgically removed tissue of medial frontal gyrus from control
subjects (non-AD) and from AD patients. (A) A representative example of a western blot illustrating GluN1, α7 nAChR and GABAAR α1 protein levels
in total tissue lysates (Input) and pulled-down (Pull Down) samples from non-AD and AD cortical homogenates. (B-C) Quantification of total GluN1
(B) and total α7 (C) in lysates from non-AD and AD homogenates (both normalized to stain-free gel). (D-F) Quantification of α7 pulled-down
(normalized to stain-free gel) (D), of GluN1 pulled-down with α7 (normalized to the pulled-down α7) (E), and of GluN1 pulled-down with α7 (data
normalized to pulled-down α7 and then further normalized to total GluN1 levels in input samples) (F). In B-F, the control group (non-AD) is set to 1,
and values are shown as mean ± SEM. *p < 0.05, **p < 0.01 and ****p < 0.0001 indicate statistical significant difference from control subjects in
unpaired t-tests, n = 8 (non-AD) and n = 7 (AD).
https://doi.org/10.1371/journal.pone.0189513.g002
α7 nAChR/NMDAR complex formation in healthy and Alzheimer brain tissue
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CA) with the setting of 2.5A and 25V for 35 min. Membranes were then washed for 4 x 5 min
with Tris-buffered saline, TBS (20 mM Tris and 150 mM NaCl, pH 7.5), supplemented with
0.05% (v/v) Tween-20 (TBS-T) and blocked in TBS supplemented with 5% (w/v) dry skim milk
(Biorad) while gently shaking for 1 h at RT. Next the membranes were incubated in blocking
buffer supplemented with primary antibodies against α7 (1:1000, #M220, Sigma), γ-aminobu-
tyric acid type A receptor (GABAAR) α1 subunit (1:500, sc-7348, Santa Cruz Biotechnology,
Heidelberg, Germany), β-actin (1:2000, #A5060, Sigma) or NMDAR subunits GluN1 (1:500,
#556308) or GluN2A (1:250, #612286) (BD Pharmingen, New Jersey, USA) for 14–16 h at 4˚C
in a humidified chamber. Then the membranes were washed for 4 × 5 min in TBS-T and incu-
bated for 1 h at 23˚C in the blocking buffer supplemented with the corresponding horse radish
peroxidase-conjugated secondary antibodies (Dako, Glostrup, Denmark). After washing the
membranes in TBS-T for 4 × 5 min, protein bands were detected by enhanced chemilumines-
cence Western Lightning ECL Pro (Perkin Elmer, Waltham, MA) and visualized using Molecu-
lar Imager1 ChemiDocTM XRS+ imaging system (Biorad) with its ImageLab program for
quantification of blots. Means of bands optical densities were measured and their correspond-
ing background subtracted.
The primary antibodies used for the GluN1, GluN2A, GluN2B and GABAAR α1 subunits
in the western blotting experiments have been shown to be specific for their respective pro-
teins. The specificity of the GluN1 antibody has been verified on WT and GluN1 KO mice
(region-specific deletion of the gene in cortex) by western blotting [22]. The specificity of the
GluN2A antibody has been verified on forebrain tissue from WT and mutant mice deficient
in GluRepsilon-1 (GluN2A) in western blotting [23], and the GluN2A and GluN2B antibodies
have been shown to be specific in western blotting studies on tissue from GluN2A(CTR) and
GluN2B(CTR) mutant mice [24]. The GABAAR α1 antibody has been used in western blotting
studies demonstrating GABAAR α1 expression in rat brain, cerebellum and retinal tissues and
using rat heart tissue as a negative control [25, 26]. The specificity of the α7 nAChR antibody
will be addressed in detail in the Results section.
Table 1. Clinicopathologic data of patients and human brain materials.
Diagnosis Age Gender pH PMD (h:min) Braak stage
Non-AD 60 F 6.27 06:50 1
Non-AD 60 F 6.80 07:30 1
Non-AD 62 M 6.36 07:20 1
Non-AD 78 M 6.52 <17:40 1
Non-AD 87 M 7.11 08:00 1
Non-AD 87 F 6.91 08:00 2
Non-AD 97 F — 10:00 2
Non-AD 90 F 6.54 06:10 3
AD 67 F 6.73 03:30 5
AD 58 M 6.29 05:15 6
AD 58 M 6.42 06:25 6
AD 59 M 6.26 05:05 6
AD 62 M 6.31 04:15 6
AD 62 F 6.53 04:25 6
AD 62 F 6.06 04:45 6
Keys: F, female; M, male; PMD, postmortem delay.
https://doi.org/10.1371/journal.pone.0189513.t001
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Statistical analyses
All data in this study are presented as mean ± S.E.M. values. The statistical analysis was per-
formed using GraphPad Prism version 7 for Windows (GraphPad Software, San Diego, CA).
Data from the affinity purification experiments analyzed with Kruskal-Wallis test followed by
Dunn’s multiple comparison test (multiple groups) or unpaired student’s t-test (two groups).
p< 0.05 was considered statistically significant.
Results
Complex formation between α7 nAChR and NMDAR in murine and
human brain tissue
As outlined in the Introduction, previous studies by the Liu group have demonstrated complex
formation between native α7 nAChRs and NMDAR in rodent brain tissue by means of co-
Fig 3. Complex formation between α7 nAChR and NMDAR in the adult 3xTg-AD mouse brain. Affinity purification performed with agarose beads
covalently coupled with α-bungarotoxin (BGT) or BSA (Ctrl) using frontal cortical tissue lysates from adult 3xTg-AD mice (76–84 weeks old) and age-
and sex-matched WT mice. (A) A representative example of a western blot illustrating GluN1, α7 nAChR and GABAAR α1 protein levels in total lysates
(Input) and pulled down (Pull Down) samples from WT and 3xTg-AD mouse cortical homogenates. (B-C) Quantification of total GluN1 (B) and total α7
(C) in lysates from WT and 3xTg-AD mouse cortical homogenates (both normalized to stain-free gel). (D-E) Quantification of α7 pulled-down
(normalized to stain-free gel) (D), and of GluN1 pulled-down with α7 (normalized to the pulled-down α7) (E). In B-E, the control group (WT) is set to 1,
and values are shown as mean ± SEM. **p < 0.01 indicates statistical significant difference from WT group in unpaired t-tests, n = 8 (WT) and n = 8
(3xTg-AD).
https://doi.org/10.1371/journal.pone.0189513.g003
α7 nAChR/NMDAR complex formation in healthy and Alzheimer brain tissue
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immunoprecipitation techniques [11–13]. In the present study, we initially set out to challenge
these observations and investigated the putative formation of α7 nAChR/NMDAR complexes
in both murine and human brain tissues. For this, we used another experimental set-up than
that used by the Liu group, performing affinity purification using bead-coupled BGT. In this
method, the highly selective high-affinity α7 nAChR antagonist BGT serves as an alternative
approach to antibodies to affinity purify α7 nAChRs and the proteins interacting with this
receptor (the “Pull Down” sample) from the total protein in the homogenates (the “Input”
sample).
As can be seen from Fig 1A, the GluN1 subunit was co-purified with α7 pulled-down from
both mouse cortical and hippocampal homogenates, as evidenced by the bands detected by
antibodies for the GluN1 and α7 subunits with approximate molecular masses of 120 kDa and
55 kDa, respectively. In parallel, we also found GluN1 to be co-purified with α7 pulled-down
Fig 4. Complex formation between α7 nAChR and NMDAR in the young 3xTg-AD mouse brain. Affinity purification performed with agarose beads
covalently coupled with α-bungarotoxin (BGT) or BSA (Ctrl) using frontal cortical tissue lysates from young 3xTg-AD mice (22–24 weeks old) and age- and
sex-matched WT mice. (A) A representative example of a western blot illustrating GluN1, α7 nAChR and GABAAR α1 protein levels in total lysates (Input)
and pulled down (Pull Down) samples from WT and 3xTg-AD mouse cortical homogenates. (B-C) Quantification of total GluN1 (B) and total α7 (C) in
lysates from WT and 3xTg-AD mouse cortical homogenates (both normalized to stain-free gel). (D-E) Quantification of α7 pulled-down (normalized to stain-
free gel) (D), and of GluN1 pulled-down with α7 (normalized to the pulled-down α7) (E). In B-E, the control group (WT) is set to 1, and values are shown as
mean ± SEM, and statistical analysis for differences from WT group in unpaired t-tests was performed, n = 7 (WT) and n = 8 (3xTg-AD).
https://doi.org/10.1371/journal.pone.0189513.g004
α7 nAChR/NMDAR complex formation in healthy and Alzheimer brain tissue
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from human cortical and hippocampal homogenates (Fig 1B). Importantly, the GABAAR α1
subunit was not detected in significant levels in the purified samples, even though the subunit
in agreement with the literature clearly was expressed in both cortical and hippocampal lysates
(Fig 1). Moreover, neither α7 nor GluN1 was detected in the pulled-down fractions obtained
using beads coated with BSA for the affinity purification (Ctrl, Fig 1). We also found the
GluN2A to be co-purified with α7 in the Pull Down samples (Fig 1D and 1E), but we
Fig 5. Complex formation between α7 nAChR and NMDAR in the presence of oligomeric Aβ1–42. Affinity purification performed with agarose beads
covalently coupled with α-bungarotoxin (BGT) or BSA (Ctrl) using homogenates of human cortical tissue pretreated with various concentrations of oligomeric
Aβ1–42. (A) A representative example of western blots illustrating GluN1 and α7 nAChR protein levels in total tissue lysates (Input) and pulled-down (Pull
Down) samples from human cortical homogenates pretreated with buffer or buffer supplemented with various concentrations of oligomeric Aβ1–42. The two
blots are from experiments performed in different days. (B-C) Quantification of α7 pulled-down (normalized to stain-free gel) (B) and GluN1 pulled-down with
α7 (normalized to the pulled-down α7) (C). In B and C, the control group (BGT pull-down without Aβ1–42, given as “0” in the figure) is set to 1, and values are
shown as mean ± SEM (n = 3). The experiments were performed in duplicate for Aβ1–42 concentrations 0.32, 1.6 and 8.0 nM and in triplicate for Aβ1–42
concentrations 40, 200 and 1000 nM using homogenates from three different human cortices. *p <0.05, **p < 0.01 and ****p < 0.0001 indicate statistical
difference from the vehicle-treated group in a Kruskal-Wallis test with Dunn’s multiple comparison test.
https://doi.org/10.1371/journal.pone.0189513.g005
α7 nAChR/NMDAR complex formation in healthy and Alzheimer brain tissue
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consistently obtained more robust signals using the antibody for GluN1 than that for GluN2A.
Since GluN1 is an integral subunit in all NMDARs in vivo [5] and detection of this subunit in
the Pull Down samples thus is representative for the receptors, we decided to focus on this sub-
unit throughout the study.
To further validate the apparent α7 nAChR/NMDAR complex formation observed in
these experiments, we next studied the co-purification of the two receptors from cortical tis-
sue from α7 KO mice [20]. Whereas both α7 and GluN1 was detected in the pulled-down
sample from WT mouse cortex homogenate (analogously to the data in Fig 1A), neither of
the two subunits could be detected in the corresponding sample from α7 KO cortical
homogenate (Fig 1C). Another important observation made in this control experiment was
the complete lack of α7 subunit in BGT pull-down from α7 KO homogenate, which con-
trasted the substantial band observed in the “Input” lane loaded with α7 KO homogenate
(Fig 1C, S2 Fig). Several commercial α7 antibodies have been shown to be non-selective [27,
28], and this property also seems to apply for the antibody used in this study. However, con-
sidering the complete lack of an “α7-sized” band in the BGT pull-down from α7 KO
homogenate, the α7-sized bands detected in the BGT pull-downs from homogenates from
WT murine tissue (and human tissues) reflect specific immunodetection of the α7 nAChR
with negligible non-specific binding of the antibody to other proteins. Hence, the use of the
specific α7 nAChR antagonist BGT for the pull down means that none of the “non-α7” pro-
teins targeted by this α7 antibody is present in the Pull Down sample, and the subsequent
immunodetection of α7 using the antibody is thus a true reflection of the α7 protein present
in the Pull Down sample.
In the next experiments, we probed the sensitivity of the apparent α7 nAChR/NMDAR
complex formation in murine cortical homogenate to the α7-pep2 and α7-pep1 peptides.
α7-pep2 (a 10-residue peptide with a sequence identical to the Leu336-Met345 region of the sec-
ond intracellular loop of α7) has been shown to eliminate the co-immunoprecipitation of
GluN2A with α7 nAChR, while α7-pep1 (a 10-residue peptide with a region identical to the
Arg316-Gly325 fragment of the second intracellular loop of α7) was shown to be without effect
[11]. Preincubation with α7-pep2 (10 μM and 50 μM) or α7-pep1 (10 μM and 50 μM) did not
affect the levels of α7 pulled-down from the homogenates substantially (Fig 1D and 1E). In
contrast, preincubation with α7-pep2 resulted in significantly reduced levels of GluN1 in the
pulled-down sample (56% and 74% reductions observed for 10 μM and 50 μM α7-pep2,
respectively), whereas preincubation with α7-pep1 (10 μM and 50 μM) did not change GluN1
levels substantially compared to the control samples (Fig 1D and 1E). Analogously, the level of
the GluN2A subunit in pulled-down samples was substantially reduced by preincubation with
10 μM α7-pep2 and significantly reduced by preincubation with 50 μM α7-pep2 (47% and
58% reductions, respectively) but not by preincubation with α7-pep1 (10 μM and 50 μM) (Fig
1D and 1E).
All in all, the co-purifications of α7 nAChR and NMDAR subunits (mostly GluN1)
from murine and human cortices and hippocampi are supported by all findings in the con-
comitantly performed control experiments. The complete absence of the subunits in Pull
Down samples in experiments using BSA-coated beads or α7 KO cortical homogenate
strongly suggest that any protein detected in the pulled-down sample is attributable to
the α7 nAChR/BGT interaction, and that the presence of GluN1 and GluN2A (but not
GABAAR α1) in the samples thus likely can be ascribed to an interaction between α7 and
the NMDAR, either directly or via other proteins. The ability of the small α7-pep2 peptide
to antagonize this interaction further supports that the co-purification of the receptors
arises from a specific interaction.
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Complex formation between α7 nAChRs and NMDARs in AD brain
tissue
In view of the key roles of glutamatergic and cholinergic transmission in processes underlying
cognitive functions and the dysfunctions in these neurotransmitter systems associated with
AD and other forms of dementia, we decided to investigate the formation of the α7 nAChR/
NMDAR complex in AD brain tissue. Applying the same method as in the experiments above,
the levels of the α7 and GluN1 subunits in pull-down samples from homogenates from post
mortem surgically removed tissue of medial frontal gyrus from 7 AD patients and from 8 indi-
viduals not suffering from AD (non-AD) were investigated.
The expression levels of both α7 and GluN1 in the homogenates from the non-AD and AD
cortical tissues were found to differ significantly (see Input lanes in Fig 2A). While the appar-
ent expression of α7 nAChR in the AD homogenate was dramatically increased (258%) com-
pared to the non-AD homogenate, the expression level of GluN1 was significantly decreased
(36%) in the AD homogenate compared to the non-AD homogenate (Fig 2B and 2C). The
observation for GluN1 was in concordance with findings in several studies of NMDAR or
GluN1 expression levels in cortical [29, 30] and hippocampal [31] autopsies from AD patients.
While most studies of α7 nAChR expression in AD cerebral cortex tissues have found receptor
levels to be moderately decreased (reviewed in [32, 33]), some studies have also observed
increased α7 nAChR expression (see for example [34, 35]).
Not surprisingly, the substantially higher total α7 nAChR expression in the AD cortical
lysates resulted in ~2-fold higher levels of α7 nAChR in the pull-downs from AD homogenates
compared to non-AD homogenates (Fig 2D). Interestingly, the GluN1/α7 ratio detected in the
purified samples from AD homogenate was dramatically lower than that from non-AD
homogenate (Fig 2E). This difference also existed when the GluN1/α7 ratio pulled-down was
normalized to total GluN1 in the homogenates, thus taking the lower GluN1 expression in the
AD lysates compared to the non-AD control lysates into account (Fig 2F). Thus, co-purifica-
tion of the GluN1 subunit with α7 was reduced with 89% (Fig 2E) and 79% (Fig 2F) in the AD
samples compared to the non-AD. The reduced GluN1 levels in the pulled-down samples
from AD compared to non-AD cortical homogenates are also directly visible from the repre-
sentative data presented in Fig 2A.
Complex formation between α7 nAChR and NMDAR in brain tissue from
3xTg-AD mice
The apparent decreased degree of α7 nAChR/NMDAR complex formation detected in the
human AD cortical homogenate compared to its control group prompted us to investigate
whether the same reduction could be observed in 3xTg-AD mice compared to WT mice. The
3xTg-AD mouse is a triple-transgenic mouse model for AD harbouring PS1-M146V, APP
(Swe) and tau-P301L transgenes that exhibit an age-related neuropathological progression pat-
tern and comprises both amyloidosis and tau pathology and develops plaques and tangles [17].
Aβ load and Aβ plaque numbers as well as tau hyperphosphorylation have been found to be
dramatically increased in hippocampus and frontal cortex from 9–12 months olds old 3xTg-
AD mice compared to 6 months old animals [36], and the mice also develop synaptic dysfunc-
tions, including LTP deficits, in an age-dependent manner [17]. In view of these age-depen-
dent differences in amyloidosis and tau pathology and the phenotypes of these mice, we
investigated and compared the α7 nAChR/NMDAR complex formation in both adult and
young 3xTg-AD mice to those in age-and sex-matched WT mice controls.
Adult 3xTg-AD mice. In contrast to the significant differences observed between total α7
and GluN1 expression in AD and non-AD cortical homogenates, the expression levels of the
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two subunits in cortical homogenates from adult 3xTg-AD mice (76–84 weeks old) and age-
and sex-matched nontransgenic controls were highly comparable (Fig 3A–3C). The similar
GluN1 levels observed in the cortical homogenates from the two mice is supported by a previ-
ous report finding no significant difference between GluN1 levels in hippocampal tissues from
3xTg-AD and WT mice [37]. As for α7 nAChR, expression levels of this receptor in different
CNS regions of 3xTg-AD mice have previously been reported to be similar or modestly
decreased compared to the levels in non-transgenic controls [38, 39]. The comparable expres-
sion levels of α7 and GluN1 in adult 3xTg-AD and adult WT mouse cortex allowed us to make
a direct comparison of levels of the two subunits detected in the pulled-down samples from
the two homogenates. As one would expect from BGT-based affinity purification from two
homogenates characterized by comparable α7 nAChR expression, α7 levels detected in the
pull-downs from 3xTg-AD and WT homogenates were very similar (Fig 3D). In contrast, the
GluN1/α7 ratio determined in the 3xTg-AD pulled-down samples was significantly reduced
(44%) compared to that determined in the control samples (Fig 3E). Thus, the absolute reduc-
tion in GluN1/α7 ratio in the 3xTg-AD pull-down compared to the WT control was somewhat
lower than that observed in the analogous experiments using human AD and non-AD cortical
homogenates (Fig 2E and 2F). Importantly, however, the fact that significantly reduced frac-
tions of GluN1 was co-purified with α7 from both human AD and 3xTg-AD cortical homoge-
nates strongly suggested that this could be a trait arising from AD-related processes.
Young 3xTg-AD mice. As outlined above, the expression levels of both α7 and GluN1 in
the cortical homogenates from adult 3xTg-AD mice and their controls were comparable (Fig
3A–3C). Analogously, the expression levels of neither α7 nor GluN1 differed significantly in
cortical homogenates from the young animals (22–24 weeks old) compared to age-and sex-
matched nontransgenic controls (Fig 4A–4C). In the case of α7, this was also reflected in the
comparable levels of α7 detected in the pull-down samples from the two mice (Fig 4D). Inter-
estingly, in contrast to the different levels of GluN1 pulled-down with α7 from adult 3xTg-AD
and adult WT mouse cortical homogenates, the GluN1/α7 ratios determined in the BGT pull-
down samples from cortical homogenates from young 3xTg-AD and young WT mice were
highly similar (Fig 4E). Thus, whether the levels of GluN1 detected in BGT pull-down samples
from cortical homogenates from this triple-transgenic mouse AD model differed significantly
compared to those in pull down samples from the WT controls was clearly dependent on the
age of the 3xTg-AD mice.
Complex formation between α7 nAChR and NMDAR is disrupted by
oligomeric Aβ1–42
Next, we sought to elucidate the molecular mechanism underlying the significantly reduced
degrees of co-purification of α7 nAChR and NMDAR from the cortical homogenates from
human AD compared to non-AD controls and from adult 3xTg-AD mice compared to age-
matched controls. Here our attention turned to the Aβ1–42 peptide, a main component of the
amyloid plaques formed in AD and one of the key pathological hallmarks of the disease [40,
41], which also has been found to be expressed at substantially higher levels in adult 3xTg-AD
mouse brain tissue than in young animals [17, 36]. This prompted us to investigate whether
Aβ1–42 in its oligomeric form could affect the formation of the α7 nAChR/NMDAR complex
in human cortical homogenates (from non-AD individuals) (Fig 5).
Whereas pretreatment of human cortical homogenates with low Aβ1–42 concentrations
(0.32 and 1.6 nM) did not change the levels of α7 in the BGT pull-down samples, higher pep-
tide concentrations (8.0, 40, 200 and 1000 nM) resulted in somewhat reduced levels of the sub-
unit in the pulled-down samples, with 8 nM and 40 nM Aβ1–42 giving rise significant decreases
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of 37% and 35%, respectively (Fig 5B). More strikingly, whereas pretreatment with low Aβ1–42
concentrations (0.32 and 1.6 nM) did not affect the levels of GluN1 co-purified with α7 signifi-
cantly, higher Aβ1–42 concentrations induced robust reductions in the GluN1/α7 ratio in the
pulled-down samples, with 8, 40, 200 and 1000 nM Aβ1–42 giving rise to 44%, 42%, 60% and
79% reduced ratios compared to the control (Fig 5C). Importantly, it should be stressed that
the reduced α7 levels detected in the BGT pull-down samples from homogenate pretreated
with the higher Aβ1–42 concentrations (Fig 5B) can not explain the reduced GluN1/α7 ratios in
the same samples: if anything, the reduced α7 levels in these samples could mean that the
reductions in the GluN1/α7 ratio have been underestimated. In conclusion, pretreatment with
oligomeric Aβ1–42 seemed to antagonize the formation of the α7 nAChR/NMDAR complex in
the human cortical homogenate in a concentration-dependent manner.
Discussion
The fairly recent realization that the trafficking, cellular distribution and function of neuro-
transmitter receptors can be dynamically modulated by their assembly into multimeric com-
plexes has introduced another level of complexity to neurotransmission, and particularly the
functional implications of GPCR oligomerization have been explored extensively [42]. The
trafficking and signaling of LGICs are regulated via their interactions with various intracellular
scaffold and adaptor proteins [43–45], and the receptors have also been proposed to form
complexes with GPCRs [46–50]. While the proposed α7 nAChR/NMDAR complex was the
first report of complex formation between two LGICs, the recent demonstration of direct
interaction and cross-inhibition between α6-containing nAChRs and P2X2/3 purinergic
receptors in dorsal root ganglia cells [51] further supports the notion that members from dif-
ferent LGIC families can assemble into multimeric complexes.
To date, the α7 nAChR/NMDAR complex formation proposed by the Liu group [11–13]
has not been verified by other groups. This work thus represents the first data from another
lab supporting the existence of this complex in brain tissues, and it also provides additional
insights into the assembly. Applying affinity purification based on BGT-coupled beads and
subsequent immunodetection of α7 and NMDAR subunits in the BGT pull-down, the two
receptors have been co-purified from murine and human brain tissues (Fig 1A and 1B).
Together with the original demonstration of the complex in rat brain tissue [11], these data
suggest that the complex may exist in several species, including the human brain. Moreover,
whereas Li et al. co-immunoprecipitated α7 nAChR and NMDAR from rat hippocampal and
amygdala tissues but not from prefrontal cortex homogenate [11], we consistently co-purified
the receptors from hippocampal as well as cortical tissues, suggesting that this complex forma-
tion is widespread in the brain (Fig 1A and 1B). This apparent discrepancy between the find-
ings in Liu et al. [11] and this work could be rooted in different sensitivities of the co-
immunoprecipitation method and the affinity purification assay used here. Whereas BGT dis-
plays high affinity and selectivity for α7 nAChRs, commercial α7 antibodies have consistently
been found to be non-selective [27, 28], and the use of BGT for the pull-down may thus pro-
vide a higher signal-to-noise ratio that could facilitate co-purification of the receptors from tis-
sues from additional brain areas.
The control experiments performed using the affinity purification assay collectively sub-
stantiate that the co-purification of α7 nAChRs and NMDARs from the human and murine
brain tissues is reflective of a specific interaction between the two receptors. The absence of
both α7 and GluN1 in BGT pull-down samples from α7 KO mice cortical homogenate both
confirms the specificity of BGT-coated beads and that the intensities of α7 bands detected in
the pull-down samples are reliable reflections of the actual α7 nAChR levels (Fig 1C).
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Furthermore, it also demonstrates that presence of GluN1 in the BGT pull-down is completely
dependent on α7 nAChR being present in the homogenate, and the absence of GABAAR α1 in
the pull-downs further supports the specificity of the α7 nAChR-NMDAR interaction (Fig 1).
Finally, the reduced NMDAR subunit levels detected in the BGT pull-downs upon pretreat-
ment of cortical homogenates with the α7-pep2 peptide also substantiate that the co-purifica-
tion is the result of a specific interaction (Fig 1D and 1E).
While the results of the control experiments thus support the formation of the α7 nAChR/
NMDAR complex, it is important to keep a general concern associated with use of biochemical
approaches to demonstrate protein-protein interactions in mind [52]: the fact that the concen-
trations of all proteins in the homogenates will be vastly increased compared to the endoge-
nous expression levels in neurons and that assay conditions differ substantially from those in
native tissues could potentially trigger assembly of proteins into complexes that are either not
formed or are of a more transient nature in vivo. Moreover, the molecular basis for α7
nAChR/NMDAR assembly also remains to be fully elucidated. The complex has been pro-
posed to be rooted in a direct interaction between α7 nAChR and GluN2A [11], but it seems
premature to rule out the involvement of additional proteins (other than α7 and the NMDAR
subunits) in the assembly. For example, α7 nAChRs associate with a wide range of scaffold and
adaptor proteins, including PDZ-containing proteins such as PSD-95 that also interacts
directly with the C-termini of NMDARs (reviewed in [53])
The significantly reduced degree of α7 nAChR/NMDAR complex formation detected in
AD cortical homogenates compared to non-AD controls is perhaps the most interesting find-
ing of this study (Fig 2). Importantly, the analogous reduction in GluN1 co-purified with α7
from cortical homogenates from adult 3xTg-AD mice compared to age-matched controls fur-
ther supports that these reductions may be attributable to specific processes related to amyloid-
osis and/or tauopathy, in particular in the light of the comparable GluN1/α7 ratios observed in
young 3xTg-AD and age-matched controls (Figs 3 and 4). As outlined in Results, the different
GluN1/α7 ratios in the AD and non-AD pull-downs can not be explained by the different
expression levels of α7 and GluN1 in the two tissues, and this is further evident from the differ-
ent GluN1/α7 ratios in pull-down samples from adult 3xTg-AD and WT mouse cortical
homogenates characterized by comparable expression levels of the two subunits (Figs 2 and 3).
Instead, the reduced GluN1 levels detected in the BGT pull-downs from the human AD and
adult 3xTg-AD homogenates compared to their respective controls appear to arise from an
impaired interaction between α7 nAChR and NMDAR, be it a direct interaction or one medi-
ated via other proteins.
The reduced degree of α7 nAChR/NMDAR complex formation in AD compared to non-
AD brain tissue could arise from numerous factors. However, the key role of Aβ1–42 for AD
pathology [40, 41] and the clear age-dependent nature of the observed reduction in GluN1/α7
ratios in the BGT pull-down samples from 3xTg-AD cortex (Figs 3 and 4) prompted us to
investigate the effect of the peptide on the formation of this putative complex. The fact that
oligomeric Aβ1–42 mediated reductions in GluN1 levels in the BGT pull-downs in a concentra-
tion-dependent manner offered a plausible molecular mechanism for the reduced α7 nAChR/
NMDAR complex formation in the AD tissue (Fig 5). Whereas it has yet to be established con-
clusively whether Aβ oligomers bind NMDARs [54, 55], a substantial amount of evidence indi-
cates that Aβ1–42 and other Aβ peptides act directly at α7 nAChRs (reviewed in [56]).
However, the reported binding affinities and the modulatory potencies of Aβ1–42 at recombi-
nant and native α7 nAChRs have varied considerably, which probably can be ascribed to the
different assays, cell/neuron cultures and soluble oligomeric Aβ1–42 preparations used in the
studies (reviewed in [56]). Thus, the nanomolar Aβ1–42 concentrations found to give rise to
significantly reduced GluN1/α7 ratios in the BGT pull-downs in this study are in good
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agreement with some, but not all, of these previous findings (Fig 5C). Another pertinent ques-
tion is whether the nanomolar concentrations of oligomeric Aβ1–42 antagonizing the α7
nAChR/NMDAR complex formation in human cortical homogenate can be said to be recon-
cilable with the reduced GluN1/α7 ratios observed in cortical tissues from the AD brain and
adult 3xTg-AD mouse brain. i.e. whether or not the reduced ratios here can be ascribed to the
endogenous Aβ1–42 concentrations in the diseased tissues (Figs 3–5). Such comparisons are
tricky, since determinations of Aβ1–42 concentrations in AD brain tissues in the literature vary
a lot depending on the analytical methods used, the brain tissue preparations investigated and
other factors [57, 58], and since Aβ1–42 densities or concentrations not necessarily are accurate
representations of the extracellular concentrations of the peptide. Aβ1–42 concentrations in
cerebrospinal fluid (CSF) or brain interstitial fluid of AD patients have been reported to be in
the 500–1000 pM range, and the concentrations of the peptide in 3xTg-AD mouse CSF have
been determined to 0.5–1.5 μg/L (~100–300 pM) [41, 59]. Although these levels clearly are
considerably lower than the effective concentrations exhibited by Aβ1–42 in the experiments in
Fig 5C, it is not clear to which extent these CSF concentrations of Aβ1–42 are representative for
the extracellular concentrations of the peptide in the AD brain. In light of this, we will refrain
from drawing too rigid conclusions as to the molecular mechanism underlying the reduced α7
nAChR/NMDAR complex formation in AD brain tissue and the role of Aβ1–42 for it. It does
seem plausible that binding of oligomeric Aβ1–42 to α7 could disrupt molecular interactions
between the two receptors in the α7 nAChR/NMDAR complex, or between α7 and another
protein in a multimeric complex, and break down the complex. On the other hand, the effect
could also be rooted in a more indirect mechanism, since oligomeric Aβ1–42 and other Aβ pep-
tide mediates a wide range of molecular and cellular effects in the AD brain [40, 41]. Finally,
we cannot rule out that non-amyloidogenic processes in the AD brain could contribute signifi-
cantly to the reduced α7 nAChR/NMDAR complex formation in AD brain tissue.
Conclusion
The present work suggests that the α7 nAChR/NMDAR complex is formed in both the rodent
and human CNS, and that formation of this complex is significantly decreased in the AD brain
compared to the healthy brain, with oligomeric Aβ1–42 being a plausible key molecular deter-
minant of this difference. However, presently very little is known about the importance of
such a complex in the healthy and diseased brain. Furthermore, demonstration of protein-pro-
tein interactions in native tissues beyond any reasonable doubt is not trivial and requires a sub-
stantial amount of evidence obtained by different methodologies. Thus, the present findings
should be considered a contribution to an ongoing exploration of this putative complex and its
physiological roles, and it will be important to confirm or challenge the existence of the com-
plex in vivo in future studies based on other approaches. The sheer possibility of the formation
of a complex comprised of Glu and ACh receptors that may be disrupted by Aβ peptides
should warrant and fuel such explorations.
Supporting information
S1 Fig. A. Aβ1–42 oligomer formation assessed by native western blotting. Silver stain of the fol-
lowing proteins (lanes): A) Aβ1–42 monomers, B) Aβ1–42 oligomers, C) fibrils, D) N-DMEM.
There is considerable background staining, and the sensitivity of the Aβ1–42 antibody is not
great. Nevertheless, clear bands at around 40 and 55 kDa can be observed in lane B (shown by
black box), suggesting that the prepared Aβ1–42 mixture contains 10-16-mers. B. Aβ1–42 oligo-
mer formation assessed at different times (after 3, 6, 9 and 24 h) using transmission electron
microscopy (TEM) imaging. The experiments were performed as previously described [60, 61].
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Briefly, 2 μl of the diluted samples (20 μM) were prepared by placing on a carbon-coated grid.
The samples were stained with 1% uranylacetate and then placed on a clean paper for removing
excess staining solution. The grids were thoroughly examined using TEM (JEOL 1010, Japan).
(PDF)
S2 Fig. The identity of the band detected with the the α7 antibody in the BGT pull-down
samples. Total homogenates (pre pull-down, Input) and pulled-down samples from two α7
WT and two α7 KO mouse cortical homogenates were submitted to gel electrophoresis and
western blotting followed by detection using the α7 antibody. This gel has been allowed to be
developed to full saturation (which is the reason for the intensely red colored bands in several
of the lanes). Analogously to the data in Fig 1C, the α7 antibody can detect bands (at approxi-
mately 55 kDa) in the total lysates from both WT mouse and α7 KO mouse cortical homoge-
nates, demonstrating the non-specificity of the antibody. As can be seen from the right side of
the gel, however, the intense bands (at approximately 55 kDa) observed in the two “α7 WT”
lanes for the BGT pull-down samples are contrasted by the negligible bands or complete
absence of bands in the two “α7 KO” lanes. This support the conclusion made based on Fig 1C
in the manuscript: that the protein detected by the α7 antibody in the BGT pull-down samples
is indeed the α7 nAChR.
(PDF)
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